Acute Myeloid Leukemia (AML) Hub interviewed HARMONY Alliance research leader, Professor Lars Bullinger, at the 25th Annual Congress of the European Hematology Association, virtual addition. They asked Professor Bullinger whether Big Data has changed our view of AML risk classification − watch the interview to find out his perspective.
Apart from leading the HARMONY Work Package on Definition of Outcomes, Professor Bullinger, Charité Berlin, is also leading a HARMONY Research Project that aims to use Big Data to revise treatment strategies in AML by identifying how certain gene–gene interactions influence disease progression. These large data sets could also be used to identify genetic mutations that predict treatment response in different patient subgroups.
“Currently there are already six molecular markers incorporated into the European LeukemiaNet guidelines, but now having put together over 5,000 data sets across Europe, we have the power to identify additional gene–gene interactions that can provide additional prognostic information.”
Professor Bullinger
Read more about the interview on the AML Hub website. The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on AML.
Learn more about the AML HARMONY research project | View findings from the proof-of-principle study
The HARMONY Alliance is a public-private partnership for Big Data in Hematology, established in January 2017. Our mission is to unlock and spread valuable knowledge on Hematologic Malignancies (blood cancers) among a large number of stakeholders. The ultimate goal of HARMONY is to harness and mine Big Data to speed up the development of improved treatments and treatment strategies for patients.
We currently have 53 Partners and 41 Associated Members from across 17 European countries, including 9 pharmaceutical companies and 7 European Patient Umbrella Organizations. The HARMONY Alliance is funded by the Innovative Medicines Initiative (IMI).
• Read more | Become involved
HARMONY takes action to manage COVID-19
• Read about the HARMONY COVID19 Data Platform | View more COVID19 activities
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
